title: Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
abstract: The main obstacles to successful hematopoietic stem cell transplantation for patients with chronic myeloid leukemia (CML) in blast crisis (BC) are increased post-transplant relapse and high treatment-related mortality. We report a patient with CML in BC who was treated initially with imatinib mesylate and was then concurrently treated with a nonmyeloablative stem cell transplant. Successful engraftment of donor cells followed by complete cytogenetic remission was achieved in the absence of severe therapy-related toxicities. This case demonstrates that imatinib mesylate given through nonmyeloablative transplant is a minimally toxic therapeutic approach, which does not compromise engraftment and may result in a favorable outcome in patients with CML in BC.
authors.affiliation: Department of Hematology, Singapore General Hospital.
authors.forename: L P
authors.initials: LP
authors.lastname: Koh
authors.forename: W Y K
authors.initials: WY
authors.lastname: Hwang
authors.forename: C T H
authors.initials: CT
authors.lastname: Chuah
authors.forename: Y C
authors.initials: YC
authors.lastname: Linn
authors.forename: Y T
authors.initials: YT
authors.lastname: Goh
authors.forename: C H
authors.initials: CH
authors.lastname: Tan
authors.forename: H J
authors.initials: HJ
authors.lastname: Ng
authors.forename: P H C
authors.initials: PH
authors.lastname: Tan
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate